Association of Adjuvant Hormone Therapy Timing With Overall Survival Among Patients With Hormone Receptor–Positive Human Epidermal Growth Factor Receptor-2–Negative Early Breast Cancer Without Chemotherapy-Reference-Cited by-同舟云学术

Association of Adjuvant Hormone Therapy Timing With Overall Survival Among Patients With Hormone Receptor–Positive Human Epidermal Growth Factor Receptor-2–Negative Early Breast Cancer Without Chemotherapy

Published:2022-02-15 Issue:2 Volume:5 Page:e2145934
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Fu Fangmeng¹²³,Yu Liuwen¹²³,Zeng Bangwei⁴,Chen Minyan¹²³,Guo Wenhui¹²³,Chen Lili¹²³,Lin Yuxiang¹²³,Hou Jialin¹²³,Li Jing¹²³,Li Yan¹²³,Li Shengmei¹²³,Chen Xiaobin¹²³,Zhang Wenzhe¹²³,Jin Xuan¹²³,Cai Weifeng¹²³,Zhang Kun¹²³,Chen Hanxi¹²³,Qiu Yibin¹²³,Nie Qian¹²³,Wang Chuan¹²³,Jacobs Lisa⁵

Affiliation:

1. Department of Breast Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, Fujian Province, China

2. Department of General Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, Fujian Province, China

3. Breast Cancer Institute, Fujian Medical University, Fuzhou, Fujian, Fujian Province, China

4. Administration Department of Nosocomial Infection, Fujian Medical University Union Hospital, Fuzhou, Fujian Province, China

5. Division of Surgical Oncology, Department of Surgery, Johns Hopkins School of Medicine, Baltimore, Maryland

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2789060/fu_2022_oi_211270_1644341785.87586.pdf

Reference40 articles.

1. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status.;Howlader;J Natl Cancer Inst,2014

2. Cancer statistics, 2019.;Siegel;CA Cancer J Clin,2019

3. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.;Early Breast Cancer Trialists’ Collaborative Group (EBCTCG);Lancet,2005

4. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.;Cuzick;Lancet Oncol,2010

5. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.;Early Breast Cancer Trialists’ Collaborative Group (EBCTCG);Lancet,2015

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Factors delaying non‐metastatic breast cancer adjuvant therapy and impact on prognosis in a cohort of Brazilian women;Journal of Evaluation in Clinical Practice;2024-06-06

2. Disparities in Hormone Receptor-Positive Breast Cancer;Current Breast Cancer Reports;2024-02-03

3. Treatment Disparities in Radiation and Hormone Therapy Among Women Covered by Medicaid vs Private Insurance in Cancer Registry and Claims Data;JAMA Health Forum;2023-05-05

4. Reexamining Time From Breast Cancer Diagnosis to Primary Breast Surgery;JAMA Surgery;2023-05-01

5. Survival Disparities in US Black Compared to White Women with Hormone Receptor Positive-HER2 Negative Breast Cancer;International Journal of Environmental Research and Public Health;2023-02-07